Lymphoma

A cellular RNA quality control mechanism was known to restrict replication of RNA viruses. Vanderbilt researchers have discovered it is also antiviral against DNA viruses. Read More

A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients. Read More

Vanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy. Read More

The histone deacetylase HDAC3 is required for the maturation of B cells, white blood cells that produce antibodies. Read More

Puck Ohi, Ph.D., assistant professor of Cell and Developmental Biology, has received the Leukemia & Lymphoma Society SCHOLAR award for his research on the role of enzymes that affect cell division, which has implications for treating cancer and blood disorders like leukemia and lymphoma. Read More